0935 [Dow Jones] STOCK CALL: Smith Barney says Cochlear (COH.AU) has found its "mojo" with earnings upgrades likely if current global success is sustained. Patients, clinics alike appear enamored with new Nucleus Freedom technology, which was launched at higher price, set for further modest price increases. BAHA acquisition looks like perfect fit, China appears set for rebound with COH ready to launch no frills implant, competitors still having problems with regulators. Due to stronger USD, FY05-06 EPS forecasts raised 4.2%, 0.9%. Maintains Buy recommendation, raises price target to A$38.62 from A$36.73; stock closed Friday up 47 cents at A$33.30. (WES)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$313.29 |
Change
1.350(0.43%) |
Mkt cap ! $20.48B | |||
| Open | High | Low | Value | Volume |
| $312.00 | $313.73 | $309.83 | $70.45M | 225.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16 | $312.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $313.37 | 36 | 1 |
View Market Depth
| Last trade - 16.15pm 13/08/2025 (20 minute delay) ? |
| COH (ASX) Chart |